DE69520569D1 - Mittel für die behandlung von störungen des blutgerinnungsprozess - Google Patents
Mittel für die behandlung von störungen des blutgerinnungsprozessInfo
- Publication number
- DE69520569D1 DE69520569D1 DE69520569T DE69520569T DE69520569D1 DE 69520569 D1 DE69520569 D1 DE 69520569D1 DE 69520569 T DE69520569 T DE 69520569T DE 69520569 T DE69520569 T DE 69520569T DE 69520569 D1 DE69520569 D1 DE 69520569D1
- Authority
- DE
- Germany
- Prior art keywords
- apc
- pct
- factor
- cleavage sites
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000008280 blood Substances 0.000 title 1
- 210000004369 blood Anatomy 0.000 title 1
- 238000003776 cleavage reaction Methods 0.000 abstract 4
- 108010014172 Factor V Proteins 0.000 abstract 3
- 108010054218 Factor VIII Proteins 0.000 abstract 3
- 102000001690 Factor VIII Human genes 0.000 abstract 3
- 230000007017 scission Effects 0.000 abstract 3
- 238000003745 diagnosis Methods 0.000 abstract 2
- 229960000301 factor viii Drugs 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 abstract 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 abstract 1
- 208000032170 Congenital Abnormalities Diseases 0.000 abstract 1
- 101800004937 Protein C Proteins 0.000 abstract 1
- 102000017975 Protein C Human genes 0.000 abstract 1
- 101800001700 Saposin-D Proteins 0.000 abstract 1
- 208000001435 Thromboembolism Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 102100029477 Vitamin K-dependent protein C Human genes 0.000 abstract 1
- 101710193900 Vitamin K-dependent protein C Proteins 0.000 abstract 1
- 239000003114 blood coagulation factor Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000013611 chromosomal DNA Substances 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000031169 hemorrhagic disease Diseases 0.000 abstract 1
- 229960000856 protein c Drugs 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP94201116 | 1994-04-22 | ||
| PCT/NL1995/000149 WO1995029259A1 (en) | 1994-04-22 | 1995-04-21 | Method and means for detecting and treating disorders in the blood coagulation cascade |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69520569D1 true DE69520569D1 (de) | 2001-05-10 |
| DE69520569T2 DE69520569T2 (de) | 2001-10-04 |
Family
ID=8216820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69520569T Expired - Lifetime DE69520569T2 (de) | 1994-04-22 | 1995-04-21 | Mittel für die behandlung von störungen des blutgerinnungsprozess |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6083905A (de) |
| EP (1) | EP0756638B1 (de) |
| JP (1) | JP3810080B2 (de) |
| AT (1) | ATE200225T1 (de) |
| AU (1) | AU697205B2 (de) |
| CA (1) | CA2188463C (de) |
| DE (1) | DE69520569T2 (de) |
| DK (1) | DK0756638T3 (de) |
| ES (1) | ES2157326T3 (de) |
| GR (1) | GR3036000T3 (de) |
| WO (1) | WO1995029259A1 (de) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69502451T2 (de) * | 1994-02-14 | 1998-09-24 | Univ Leiden | Verfahren zum nachweis eines genetischen defektes, assoziert mit thrombose und/oder mangelhafter anticoagulanz-reaktion auf aktiviertem protein c |
| US5705395A (en) * | 1994-11-14 | 1998-01-06 | The Scripps Research Institute | Method for diagnosis of thrombotic disorders |
| US5885971A (en) * | 1995-03-24 | 1999-03-23 | The Regents Of The University Of California | Gene therapy by secretory gland expression |
| US6531455B1 (en) * | 1995-03-24 | 2003-03-11 | The Regents Of The University Of California | Delivery of polynucleotides by secretory gland expression |
| US5874256A (en) * | 1995-06-06 | 1999-02-23 | Rijks Universiteit Leiden | Method for diagnosing an increased risk for thrombosis or a genetic defect causing thrombosis and kit for use with the same |
| GB9604267D0 (en) * | 1996-02-29 | 1996-05-01 | Royal Infirmary Of Edinburgh N | Mutation assay |
| ES2162361T3 (es) * | 1998-03-19 | 2001-12-16 | Instrumentation Lab Spa | Metodos, kits y reactivos mejorados para el muestreo de defectos de la coagulacion sanguinea. |
| DE19858278A1 (de) * | 1998-12-17 | 2000-06-21 | Dade Behring Marburg Gmbh | Verfahren zum Lokalisieren von Defekten im Gerinnungssystem |
| JP4676585B2 (ja) * | 1999-12-24 | 2011-04-27 | 一般財団法人化学及血清療法研究所 | 血液凝固異常に基づく疾患の治療・予防用医薬組成物 |
| US8914114B2 (en) | 2000-05-23 | 2014-12-16 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
| US7615622B2 (en) * | 2001-01-12 | 2009-11-10 | University Of Maryland, Baltimore | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII |
| US7125846B2 (en) * | 2001-11-09 | 2006-10-24 | Novo Nordisk Healthcare A/G | Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides |
| AU2002340779B2 (en) * | 2001-11-09 | 2007-08-02 | Novo Nordisk Health Care Ag | Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides |
| US7375100B2 (en) | 2003-06-04 | 2008-05-20 | Pfizer Inc | 2-amino-pyridine derivatives useful for the treatment of diseases |
| US7067541B2 (en) | 2003-06-04 | 2006-06-27 | Pfizer Inc | 2-amino-pyridine derivatives useful for the treatment of diseases |
| US7211559B2 (en) * | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
| JP2007530586A (ja) | 2004-03-25 | 2007-11-01 | ザ ファインスタイン インスティテュート フォー メディカル リサーチ | 神経性止血法 |
| US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
| WO2006027111A1 (en) * | 2004-09-06 | 2006-03-16 | Zlb Behring Gmbh | Modified coagulation factor viii with enhanced stability |
| US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
| EP1833559B1 (de) | 2004-12-27 | 2010-11-24 | The Feinstein Institute for Medical Research | Behandlung von entzündlichen erkrankungen durch elektrische stimulation des vagus-nervs |
| EP1945270B1 (de) | 2005-11-09 | 2011-05-25 | Alnylam Pharmaceuticals Inc. | Zusammensetzungen und verfahren zur hemmung der expression von faktor v leiden mutationsgen |
| WO2008059009A2 (en) * | 2006-11-16 | 2008-05-22 | Crucell Holland B.V. | Factor v mutants for hemostasis in hemophilia |
| WO2008059043A2 (en) * | 2006-11-16 | 2008-05-22 | Crucell Holland B.V. | Combination of coagulation factor viii with apc-resistant factor v |
| WO2008059041A2 (en) * | 2006-11-16 | 2008-05-22 | Crucell Holland B.V. | Complementation of factor xi deficiency by factor v mutants |
| US8391970B2 (en) | 2007-08-27 | 2013-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
| EP2247303A4 (de) * | 2007-12-20 | 2011-12-07 | Univ Queensland | Hämostase-modulierende zusammensetzungen und ihre verwendungen |
| US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
| US9211409B2 (en) | 2008-03-31 | 2015-12-15 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of T-cell activity |
| EP2355893B1 (de) | 2008-11-18 | 2013-12-25 | Setpoint Medical Corporation | Vorrichtungen zur optimierung der elektrodenplatzierung für antientzündungsstimulationen |
| US8996116B2 (en) | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
| US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| WO2010144578A2 (en) | 2009-06-09 | 2010-12-16 | Setpoint Medical Corporation | Nerve cuff with pocket for leadless stimulator |
| WO2014169145A1 (en) | 2013-04-10 | 2014-10-16 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
| US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
| EP2515996B1 (de) | 2009-12-23 | 2019-09-18 | Setpoint Medical Corporation | Nervenstimulatoren und systeme zur behandlung von chronischer entzündung |
| ITFI20110084A1 (it) | 2011-04-22 | 2012-10-23 | Kedrion Spa | Nuovo processo per la preparazione di un concentrato di fv virus inattivato a partire da plasma umano, scalabile a livello industriale. |
| WO2012154865A2 (en) | 2011-05-09 | 2012-11-15 | Setpoint Medical Corporation | Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| US12172017B2 (en) | 2011-05-09 | 2024-12-24 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
| US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
| US11406833B2 (en) | 2015-02-03 | 2022-08-09 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
| US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
| EP3405255A4 (de) | 2016-01-20 | 2019-10-16 | Setpoint Medical Corporation | Implantierbare mikrostimulatoren und induktive ladesysteme |
| CN114904142A (zh) | 2016-01-20 | 2022-08-16 | 赛博恩特医疗器械公司 | 迷走神经刺激的控制 |
| US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
| US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
| WO2019036470A1 (en) | 2017-08-14 | 2019-02-21 | Setpoint Medical Corporation | TESTING TEST FOR STIMULATION OF NERVE WAVE |
| US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
| WO2021236977A1 (en) | 2020-05-21 | 2021-11-25 | The Feinstein Institutes For Medical Research | Systems and methods for vagus nerve stimulation |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5451521A (en) * | 1986-05-29 | 1995-09-19 | Genetics Institute, Inc. | Procoagulant proteins |
-
1995
- 1995-04-21 AT AT95916845T patent/ATE200225T1/de not_active IP Right Cessation
- 1995-04-21 ES ES95916845T patent/ES2157326T3/es not_active Expired - Lifetime
- 1995-04-21 DE DE69520569T patent/DE69520569T2/de not_active Expired - Lifetime
- 1995-04-21 EP EP95916845A patent/EP0756638B1/de not_active Expired - Lifetime
- 1995-04-21 DK DK95916845T patent/DK0756638T3/da active
- 1995-04-21 AU AU23194/95A patent/AU697205B2/en not_active Ceased
- 1995-04-21 JP JP52755095A patent/JP3810080B2/ja not_active Expired - Fee Related
- 1995-04-21 CA CA002188463A patent/CA2188463C/en not_active Expired - Fee Related
- 1995-04-21 WO PCT/NL1995/000149 patent/WO1995029259A1/en active IP Right Grant
- 1995-04-21 US US08/722,240 patent/US6083905A/en not_active Expired - Fee Related
-
2001
- 2001-06-06 GR GR20010400853T patent/GR3036000T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1995029259A1 (en) | 1995-11-02 |
| ES2157326T3 (es) | 2001-08-16 |
| JP3810080B2 (ja) | 2006-08-16 |
| CA2188463C (en) | 2007-12-11 |
| DK0756638T3 (da) | 2001-07-23 |
| AU697205B2 (en) | 1998-10-01 |
| CA2188463A1 (en) | 1995-11-02 |
| JPH09512425A (ja) | 1997-12-16 |
| DE69520569T2 (de) | 2001-10-04 |
| US6083905A (en) | 2000-07-04 |
| EP0756638B1 (de) | 2001-04-04 |
| ATE200225T1 (de) | 2001-04-15 |
| GR3036000T3 (en) | 2001-09-28 |
| AU2319495A (en) | 1995-11-16 |
| EP0756638A1 (de) | 1997-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69520569D1 (de) | Mittel für die behandlung von störungen des blutgerinnungsprozess | |
| ATE321570T1 (de) | Verfahren zur behandlung von hämostatischen störungen durch lösliches p-selectin | |
| ATE247717T1 (de) | Apoliporotein e polymorphismen und behandlung der alzheimerkrankheit | |
| EP0796623A3 (de) | Pharmazeutisches Präparat zur Behandlung von Blutgerinnungs-störungen | |
| DE69519929D1 (de) | Verfahren und zusammensetzungen für die spezifische koagulation von tumorgefässen | |
| EA200200755A1 (ru) | Опосредованная рецептором nogo блокада роста аксонов | |
| NO920125L (no) | Fremgangsmaate for aa bestemme den funksjonelle aktivitetentil fritt protein s eller protein c i en plasmaproeve | |
| DE60126495D1 (de) | Nukleinsäure und protein, genannt 158p1d7, für die behandlung und erkennung von blasenkrebs und anderen krebsarten | |
| EP1423133A4 (de) | Behandlung von muskeldystrophien und verwandter erkrankungen | |
| EP1942186A3 (de) | Rekombinantes Plättchencollagen-Rezeptor-Glycoprotein VI und seine pharmazeutische Anwendung | |
| ES2106772T3 (es) | Variantes de pai-2. | |
| WO2002046767A3 (en) | Diagnosis and treatment of alzheimer's disease | |
| DE69705936D1 (de) | Teil der intronsequenz des von hippel-lindau(vhl)-gens und seine verwendung zur krankheitsdiagnose | |
| DE60024997D1 (de) | Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen | |
| GB9610281D0 (en) | Diagnostic method and apparatus | |
| WO1999058098A8 (en) | HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO | |
| DE59909356D1 (de) | Pharmazeutische präparation, enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen | |
| DE20213920U1 (de) | Diagnostikum zum Nachweis der den von Willebrand-Faktorspaltenden Aktivität von ADAMTS13 | |
| DE50010525D1 (de) | Verfahren zur isolierung und aufreinigung von gräserpollenallergenen | |
| ATE312914T1 (de) | Rdgb-proteine | |
| DE60311330T2 (de) | Genetisches Verfahren zur Vorhersage des Glaukomarisikos | |
| DE69928814D1 (de) | Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten | |
| Rüchel et al. | A probable cause of paradoxical thrombosis in zygomycosis | |
| Windt et al. | The hemizona assay (HZA) as an experimental model to evaluate the inhibition of sperm binding to the murine zona pellucida by isolated zona pellucida protein | |
| DE69635989D1 (de) | Diagnostischer test für von pferdearthritisvirus verursachte krankheiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |